Steven Forman, MD
Cardiovascular Disease · Los Alamitos, CANPI 1023059763
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.0%), speaking fees and education — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Medtronic at 54.9% of the total. Reporting peaked in 2019 at $5,474 and has fallen 86.2% since, to $755 in 2025.
Across 370 payments — averaging $41.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Novartis$1K
- Boehringer Ingelheim$734
- Johnson & Johnson$597
- Amgen$387
- Pfizer$384
- plus $4K from 39 others
Across 23 payments — averaging $3670.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$30K
- Cvrx, Inc.$22K
- Boehringer Ingelheim$12K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
- AstraZeneca$9K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Speaking & faculty fees$7,65050%
- Food & beverage$7,65350%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ClosureFast$5,775
- VenaSeal$1,875
- MitraClip$183
- COREVALVE EVOLUT R$169
- CoreValve Evolut$153
- Edwards SAPIEN 3 Transcatheter Heart Valve$133
- XARELTO$111
- Micra$100
How this compares
$15,311 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 14 | $308,169 |
| EliquisApixaban | 258 | $249,496 |
| XareltoRivaroxaban | 118 | $123,566 |
| EntrestoSacubitril/Valsartan | 66 | $88,832 |
| FarxigaDapagliflozin Propanediol | 52 | $43,795 |
| JardianceEmpagliflozin | 29 | $32,115 |
| BrilintaTicagrelor | 20 | $24,430 |
| Repatha SureclickEvolocumab | 18 | $18,507 |
| Metoprolol Succinate | 305 | $4,822 |
| Atorvastatin Calcium | 328 | $3,956 |
| Flecainide Acetate | 49 | $3,414 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $3,026 |
| Carvedilol | 196 | $1,951 |
| Rosuvastatin Calcium | 113 | $1,803 |
| Losartan Potassium | 154 | $1,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $384 | $557,664272 claims |
| Johnson & JohnsonXarelto | $597 | $123,566118 claims |
| NovartisEntresto | $1,087 | $88,83266 claims |
| AstraZenecaFarxiga, Brilinta | $46 | $68,22672 claims |
| Boehringer IngelheimJardiance | $734 | $32,11529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Alamitos
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.